

1. (cancel)
2. (Currently Amended) A compound of Formula I



or a pharmaceutically acceptable salt thereof, wherein:

D is -NH-C(O)-NH-,

A is a substituted moiety of up to 40 carbon atoms of the formula: -L-(M-L<sup>1</sup>)<sub>q</sub>, where

L is substituted or unsubstituted phenyl bound directly to D,

L<sup>1</sup> is phenyl or a 5 to 6 membered hetaryl moiety substituted by at least one substituent selected from the group consisting of -SO<sub>2</sub>R<sub>x</sub>, -C(O)R<sub>x</sub> and -C(NR<sub>y</sub>)R<sub>z</sub>, wherein the heteroatoms of said hetaryl moiety comprises heteroatoms consisting consist of nitrogen,

M is oxygen,

q is 1 and

B is a substituted or unsubstituted pyridyl group, a substituted or unsubstituted quinoliny group or a substituted or unsubstituted isoquinoliny group,

where B is substituted, L is substituted or L<sup>1</sup> is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W<sub>n</sub>, where n is 0-3;

~~R<sub>y</sub> is hydrogen, C<sub>1-10</sub>-alkyl, C<sub>1-10</sub>-alkoxy, C<sub>3-10</sub>-cycloalkyl having 0-3 heteroatoms, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub>-alkenoyl, C<sub>6-12</sub>-aryl, C<sub>3-12</sub>-hetaryl having 1-3 heteroatoms selected from N, S and O, C<sub>7-24</sub>-aralkyl, C<sub>7-24</sub>-alkaryl, substituted C<sub>1-10</sub>-alkyl, substituted C<sub>1-10</sub>-alkyl, substituted C<sub>1-10</sub>-alkoxy, substituted C<sub>3-10</sub>-cycloalkyl having 0-3 heteroatoms selected from N, S and O, substituted C<sub>6-14</sub>-aryl, substituted C<sub>3-12</sub>-hetaryl having 1-3 heteroatoms selected from N, S and O, substituted C<sub>7-24</sub>-alkaryl or substituted C<sub>7-24</sub> aralkyl, where R<sub>y</sub> is a substituted group, it is substituted by halogen up to per halo,~~

~~R<sub>z</sub> is hydrogen, C<sub>1-10</sub>-alkyl, C<sub>1-10</sub>-alkoxy, C<sub>3-10</sub>-cycloalkyl having 0-3 heteroatom, C<sub>2-10</sub> alkenyl, C<sub>1-10</sub>-alkenoyl, C<sub>6-12</sub>-aryl, C<sub>3-12</sub>-hetaryl having 1-3 heteroatoms selected from S, N and O, C<sub>7-24</sub>-alkaryl, C<sub>7-24</sub>-aralkyl, substituted C<sub>1-10</sub>-alkyl, substituted C<sub>1-10</sub> alkoxy, substituted C<sub>6-14</sub>-aryl, substituted C<sub>3-10</sub>-cycloalkyl having 0-3 heteroatoms selected from S, N and O, substituted C<sub>3-12</sub>-hetaryl having 1-3 heteroatoms selected from S, N and O, substituted C<sub>7-24</sub>-alkaryl or substituted C<sub>7-24</sub>-aralkyl where R<sub>z</sub> is a substituted group, it is substituted by halogen up to per halo, hydroxy, C<sub>1-10</sub>-alkyl, C<sub>3-</sub>~~

~~$C_{1-12}$  cycloalkyl having 0-3 heteroatoms selected from O, S and N,  $C_{3-12}$  hetaryl having 1-3 heteroatoms selected from N, S and O,  $C_{1-10}$  alkoxy,  $C_{6-12}$  aryl,  $C_{1-6}$  halo substituted alkyl up to per halo alkyl,  $C_6-C_{12}$  halo substituted aryl up to per halo aryl,  $C_3-C_{12}$  halo substituted cycloalkyl up to per halo cycloalkyl having 0-3 heteroatoms selected from N, S and O, halo substituted  $C_{3-12}$  hetaryl having 1-3 heteroatoms selected from O, N and S, halo substituted  $C_7-C_{24}$  aralkyl up to per halo aralkyl, halo substituted  $C_7-C_{24}$  alkaryl up to per halo alkaryl, and  $-C(O)R_g$ ;~~

$R_x$  is  $R_x$  or  $NR_aR_b$  where  $R_a$  and  $R_b$  are,

a) independently hydrogen, or selected from the group consisting of  $C_1-C_{10}$  alkyl,  $C_1-C_{10}$  alkoxy,  $C_{3-10}$  cycloalkyl,  $C_{2-10}$  alkenyl,  $C_{1-10}$  alkenoyl,  $C_{6-12}$  aryl,  $C_{3-12}$  hetaryl having 1-3 heteroatoms selected from O, N and S,  $C_{3-12}$  cycloalkyl having 0-3 heteroatoms selected from N, S and O,  $C_{7-24}$  aralkyl,  $C_7-C_{24}$  alkaryl, substituted  $C_{1-10}$  alkyl, substituted  $C_{1-10}$  alkoxy, substituted  $C_{3-10}$  cycloalkyl, having 0-3 heteroatoms selected from N, S and O, substituted  $C_{6-12}$  aryl, substituted  $C_{3-12}$  hetaryl having 1-3 heteroatoms selected from N, S and O, substituted  $C_{7-24}$  aralkyl, substituted  $C_{7-24}$  alkaryl, where  $R_a$  and  $R_b$  are a substituted group, they are substituted by halogen up to per halo, hydroxy,  $C_{1-10}$  alkyl,  $C_{3-12}$  cycloalkyl having 0-3 heteroatoms selected from O, S and N,  $C_{3-12}$  hetaryl having 1-3 heteroatoms selected from N, S and O,  $C_{1-10}$  alkoxy,  $C_{6-12}$  aryl,  $C_{1-6}$  halo substituted alkyl up to per halo alkyl,  $C_6-C_{12}$  halo substituted aryl up to per halo aryl,  $C_3-C_{12}$  halo substituted cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted  $C_3-C_{12}$  hetaryl up to per halo hetaryl, halo substituted  $C_7-C_{24}$  aralkyl up to per halo aralkyl, halo substituted  $C_7-C_{24}$  alkaryl up to per halo alkaryl, or  $-C(O)R_g$ ;

W is independently selected from the group consisting of  $-CN$ ,  $-CO_2R^7$ ,  $-C(O)NR^7R^7$ ,  $-C(O)-R^7$ ,  $-NO_2$ ,  $-OR^7$ ,  $-SR^7$ ,  $-NR^7R^7$ ,  $-NR^7C(O)OR^7$ ,  $-NR^7C(O)R^7$ ,  $C_1-C_{10}$  alkyl,  $C_1-C_{10}$  alkoxy,  $C_2-C_{10}$  alkenyl,  $C_1-C_{10}$  alkenoyl,  $C_3-C_{10}$  cycloalkyl having 0-3 heteroatoms selected from O, S and N,  $C_6-C_{14}$  aryl,  $C_7-C_{24}$  alkaryl,  $C_7-C_{24}$  aralkyl,  $C_3-C_{12}$  heteroaryl having 1-3 heteroatoms selected from O, N and S,  $C_4-C_{23}$  alkheteroaryl having 1-3 heteroatoms selected from O, N and S, substituted  $C_1-C_{10}$  alkyl, substituted  $C_1-C_{10}$  alkoxy, substituted  $C_2-C_{10}$  alkenyl, substituted  $C_1-C_{10}$  alkenoyl, substituted  $C_3-C_{10}$  cycloalkyl having 0-3 heteroatoms selected from O, N and S, substituted  $C_6-C_{12}$  aryl, substituted  $C_3-C_{12}$  hetaryl having 1-3 heteroatoms selected

from O, N and S, substituted C<sub>7</sub>-C<sub>24</sub> aralkyl, substituted C<sub>7</sub>-C<sub>24</sub> alkaryl, and substituted C<sub>4</sub>-C<sub>23</sub> alkheteroaryl having 1-3 heteroatoms selected from O, N and S;

each R<sup>7</sup> is independently selected from H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>1</sub>-C<sub>10</sub> alkenoyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms selected from O, S and N, C<sub>6</sub>-C<sub>14</sub> aryl, C<sub>3</sub>-C<sub>13</sub> hetaryl having 1-3 heteroatoms selected from O, N and S, C<sub>7</sub>-C<sub>14</sub> alkaryl, C<sub>7</sub>-C<sub>24</sub> aralkyl, C<sub>4</sub>-C<sub>23</sub> alkheteroaryl having 1-3 heteroatoms selected from O, N and S, up to per-halosubstituted C<sub>3</sub>-C<sub>13</sub> hetaryl having 1-3 heteroatoms selected from O, N and S, up to per-halosubstituted C<sub>1</sub>-C<sub>10</sub> alkyl, up to per-halosubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per-halosubstituted C<sub>6</sub>-C<sub>14</sub> aryl, up to per-halosubstituted C<sub>7</sub>-C<sub>24</sub> aralkyl, up to per-halosubstituted C<sub>7</sub>-C<sub>24</sub> alkaryl, and up to per-halosubstituted C<sub>4</sub>-C<sub>23</sub> alkheteroaryl; and

each Z is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>1</sub>-C<sub>10</sub> alkenoyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms selected from O, N and S, C<sub>6</sub>-C<sub>14</sub> aryl, C<sub>3</sub>-C<sub>13</sub> hetaryl having 1-3 heteroatoms selected from O, N and S, C<sub>7</sub>-C<sub>24</sub> alkaryl, C<sub>7</sub>-C<sub>24</sub> aralkyl, C<sub>4</sub>-C<sub>23</sub> alkheteroaryl having 1-3 heteroatoms selected from O, N and S, substituted C<sub>1</sub>-C<sub>10</sub> alkyl, substituted C<sub>1</sub>-C<sub>10</sub> alkoxy, substituted C<sub>2</sub>-C<sub>10</sub> alkenyl, substituted C<sub>1</sub>-C<sub>10</sub> alkenoyl, substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms selected from O, N and S, substituted C<sub>6</sub>-C<sub>12</sub> aryl, substituted C<sub>7</sub>-C<sub>24</sub> alkaryl, substituted C<sub>7</sub>-C<sub>24</sub> aralkyl and substituted C<sub>4</sub>-C<sub>23</sub> alkheteroaryl having 1-3 heteroatoms selected from O, N and S; wherein if Z is a substituted group, the one or more substituents are selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -COR<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>R<sup>7</sup>, -NR<sup>7</sup>C(O)R<sup>7</sup>, and -NR<sup>7</sup>C(O)OR<sup>7</sup>.

3. **(Previously Presented)** A compound as in claim 2 wherein L' is phenyl or pyridinyl.
4. **(Previously Presented)** A compound as in claim 2 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by Hydrogen.
5. **(Previously Presented)** A compound of claim 2 wherein B of Formula I is a substituted pyridyl, substituted quinolinyl or substituted isoquinolinyl group substituted 1 to 3 times by 1 or more substituents selected from the group consisting of -CN, halogen, C<sub>1</sub>-C<sub>10</sub>

alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, -OH, up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkyl, up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkoxy or phenyl substituted by halogen up to per halo.

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Previously Presented) A compound of claim 2, wherein L<sup>1</sup> is phenyl, pyridinyl or pyrimidinyl.

10. (Previously Presented) A compound of claim 5, wherein L<sup>1</sup> is phenyl, pyridinyl or pyrimidinyl.

11. (Canceled)

12. (Previously Presented) A compound of claim 2 wherein L<sup>1</sup> is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl, up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkyl, -CN, -OH, halogen, C<sub>1</sub>-C<sub>10</sub> alkoxy and up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkoxy.

13. (Canceled)

14. (Original) A compound of claim 10 wherein L<sup>1</sup> is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl, up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkyl, -CN, -OH, halogen, C<sub>1</sub>-C<sub>10</sub> alkoxy and up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkoxy.

15. (Previously Presented) A compound of claim 2 wherein L<sup>1</sup> is substituted only by -C(O)R<sub>x</sub>.

16. (Previously Presented) A compound of claim 2 wherein L<sup>1</sup> is substituted by -C(O)R<sub>x</sub> wherein R<sub>x</sub> is NR<sub>a</sub>R<sub>b</sub> and R<sub>a</sub> and R<sub>b</sub> are independently hydrogen or C<sub>1</sub> - C<sub>10</sub> alkyl.

17. (Previously presented) A compound of claim 3 wherein L<sup>1</sup> is substituted by -C(O)R<sub>x</sub>, wherein R<sub>x</sub> is NR<sub>a</sub>R<sub>b</sub> and R<sub>a</sub> and R<sub>b</sub> are independently hydrogen or C<sub>1</sub> - C<sub>10</sub> alkyl.

18. (Previously presented) A compound of claim 10 wherein L<sup>1</sup> is substituted by -C(O)R<sub>x</sub>, wherein R<sub>x</sub> is NR<sub>a</sub>R<sub>b</sub> and R<sub>a</sub> and R<sub>a</sub> are independently hydrogen or C<sub>1</sub> - C<sub>10</sub> alkyl.

19. (canceled)

20. (canceled)

21. (canceled)

22. (canceled)

23. (canceled)

24. (canceled)

25. (Previously Presented) A compound of claim 2 which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of

- a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulfonic acid, trifluorosulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and
- b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

26. (canceled)

27. (Previously Presented) A pharmaceutical composition comprising a compound of claim 2 or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.

28. (canceled)

29. (Previously Presented) A method for the treatment of solid cancers comprising administering to a host in need thereof an effective amount of a compound of Formula I of claim 2.







30. (Previously Presented) A method for the treatment of carcinomas, myeloid disorders or adenomas comprising administering to a host in need thereof an effective amount of a compound of Formula I of claim 2.




31. (canceled)

32. (canceled)

33. (canceled)









34. (Previously presented) A compound selected from the group consisting of














and pharmaceutically acceptable salts thereof.

35. (Previously presented) A pharmaceutical composition comprising a compound selected from the group consisting of



and their pharmaceutically acceptable salts, and a physiologically acceptable carrier.

36. (Previously presented) A method for the treatment of solid cancers, comprising administering to a host in need thereof an effective amount of a compound selected from the group consisting of



and pharmaceutically acceptable salts thereof.

37. **(Currently Amended)** A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein

D is  $-\text{NH}-\text{C}(\text{O})-\text{NH}-$ ,

A is of the formula:  $-L-(M-L^1)_q$ , where L is phenyl bound directly to D,  $L^1$  is pyridinyl, M is oxygen and q is 1; and

B is a substituted or unsubstituted pyridyl, quinolinyl or isoquinolinyl group, wherein  $L^1$  is substituted by  $-C(O)R_x$ ,

~~$R_x$  is hydrogen,  $C_{1-10}$ -alkyl,  $C_{1-10}$ -alkoxy,  $C_{3-10}$ -cycloalkyl having 0-3 heteroatoms selected from N, O and S,  $C_{2-10}$ -alkenyl,  $C_{1-10}$ -alkenoyl,  $C_{6-12}$ -aryl,  $C_3$ - $C_{12}$ -hetaryl having 1-3 heteroatoms selected from S, N and O,  $C_{7-24}$ -alkaryl,  $C_{7-24}$ -aralkyl, substituted  $C_{1-10}$ -alkyl, substituted  $C_{1-10}$ -alkoxy, substituted  $C_6$ - $C_{14}$ -aryl, substituted  $C_3$ - $C_{10}$ -cycloalkyl, substituted  $C_{3-12}$ -hetaryl having 1-3 heteroatoms selected from S, N and O, substituted  $C_{7-24}$ -alkaryl or substituted  $C_7$ - $C_{24}$ -aralkyl where  $R_x$  is a substituted group, it is substituted by halogen up to per-halo, hydroxy, or  $C_{1-10}$ -alkyl;~~

$R_x$  is  $R_x$  or  $NR_aR_b$  where  $R_a$  and  $R_b$  are

independently hydrogen,  $C_1$ - $C_{10}$  alkyl,  $C_1$ - $C_{10}$  alkoxy,  $C_{3-10}$  cycloalkyl,  $C_{2-10}$  alkenyl,  $C_{1-10}$  alkenoyl,  $C_{6-12}$  aryl,  $C_{3-12}$  hetaryl having 1-3 heteroatoms selected from O, N and S,  $C_{3-12}$  cycloalkyl having 0-3 heteroatoms selected from N, S and O,  $C_{7-24}$  aralkyl,  $C_7$ - $C_{24}$  alkaryl, substituted  $C_{1-10}$  alkyl, substituted  $C_{1-10}$  alkoxy, substituted  $C_{3-10}$  cycloalkyl, having 0-3 heteroatoms selected from N, S and O, substituted  $C_{6-12}$  aryl, substituted  $C_{3-12}$  hetaryl having 1-3 heteroatoms selected from N, S and O, substituted  $C_{7-24}$  aralkyl, substituted  $C_{7-24}$  alkaryl, where  $R_a$  and  $R_b$  are a substituted group, they are substituted by halogen up to per halo, hydroxy,  $C_{1-10}$  alkyl; or

where B is substituted, L is substituted or  $L^1$  is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and  $W_n$ , where n is 0-3;

wherein each W is independently selected from the group consisting of  $-CN$ ,  $-CO_2R^7$ ,  $-C(O)NR^7R^7$ ,  $-C(O)-R^7$ ,  $-NO_2$ ,  $-OR^7$ ,  $-SR^7$ ,  $-NR^7R^7$ ,  $-NR^7C(O)OR^7$ ,  $-NR^7C(O)R^7$ ,  $C_1$ - $C_{10}$  alkyl,  $C_1$ - $C_{10}$  alkoxy,  $C_2$ - $C_{10}$  alkenyl,  $C_1$ - $C_{10}$  alkenoyl,  $C_3$ - $C_{10}$  cycloalkyl having 0-3 heteroatoms selected from O, S and N,  $C_6$ - $C_{14}$  aryl,  $C_7$ - $C_{24}$  alkaryl,  $C_7$ - $C_{24}$  aralkyl,  $C_3$ - $C_{12}$  heteroaryl having 1-3 heteroatoms selected from O, N and S,  $C_4$ - $C_{23}$  alkheteroaryl having 1-3 heteroatoms selected from O, N and S, substituted  $C_1$ - $C_{10}$  alkyl, substituted  $C_1$ - $C_{10}$  alkoxy, substituted  $C_2$ - $C_{10}$  alkenyl, substituted  $C_1$ - $C_{10}$  alkenoyl, substituted  $C_3$ - $C_{10}$  cycloalkyl having 0-3 heteroatoms selected from O, N and S, substituted  $C_6$ - $C_{12}$  aryl, substituted  $C_3$ - $C_{12}$  hetaryl

having 1-3 heteroatoms selected from O, N and S, substituted C<sub>7</sub>-C<sub>24</sub> aralkyl, substituted C<sub>7</sub>-C<sub>24</sub> alkaryl, and substituted C<sub>4</sub>-C<sub>23</sub> alkheteroaryl having 1-3 heteroatoms selected from O, N and S, optionally substituted by one or more substituents independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>7</sup>, -C(O)R<sup>7</sup>, -C(O)NR<sup>7</sup>R<sup>7</sup>, -OR<sup>7</sup>, -SR<sup>7</sup>, -NR<sup>7</sup>R<sup>7</sup>, -NO<sub>2</sub>, -NR<sup>7</sup>C(O)R<sup>7</sup>, -NR<sup>7</sup>C(O)OR<sup>7</sup> and halogen up to per-halo; with each R<sup>7</sup> independently selected from H or C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>1</sub>-C<sub>10</sub> alkenoyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms selected from O, S and N, C<sub>6</sub>-C<sub>14</sub> aryl, C<sub>3</sub>-C<sub>13</sub> hetaryl having 1-3 heteroatoms selected from O, N and S, C<sub>7</sub>-C<sub>14</sub> alkaryl, C<sub>7</sub>-C<sub>24</sub> aralkyl, C<sub>4</sub>-C<sub>23</sub> alkheteroaryl having 1-3 heteroatoms selected from O, N and S, up to per-halosubstituted C<sub>3</sub>-C<sub>13</sub> hetaryl having 1-3 heteroatoms selected from O, N and S, up to per-halosubstituted C<sub>1</sub>-C<sub>10</sub> alkyl, up to per-halosubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl having 0-3 heteroatoms selected from O, N and S, up to per-halosubstituted C<sub>6</sub>-C<sub>14</sub> aryl, up to per-halosubstituted C<sub>7</sub>-C<sub>24</sub> aralkyl, up to per-halosubstituted C<sub>7</sub>-C<sub>24</sub> alkaryl, and up to per-halosubstituted C<sub>4</sub>-C<sub>23</sub> alkheteroaryl.

**38. (canceled)**

**39. (Previously Presented)** A compound as in claim 37 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by hydrogen.

**40. (Previously presented)** A compound of claim 37 wherein B of Formula I is a substituted pyridyl, substituted quinoliny or isoquinoliny group substituted 1 to 3 times by 1 or more substituents selected from the group consisting of -CN, halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, -OH, up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkyl, up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkoxy or phenyl substituted by halogen up to per halo.

**41. (canceled)**

**42. (Previously presented)** A compound of claim 37 wherein L<sup>1</sup> is additionally substituted 1 to 3 times by one or more substituents selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl, up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkyl, -CN, -OH, halogen, C<sub>1</sub>-C<sub>10</sub> alkoxy and up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkoxy.

**43. (canceled)**

**44. (canceled)**

**45. (Previously presented)** A compound as in claim 37 wherein substituents for B and L and additional substituents for L<sup>1</sup>, are selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> alkyl up to per halo substituted C<sub>1</sub>-C<sub>10</sub> alkyl, CN, OH, halogen, C<sub>1</sub>-C<sub>10</sub> alkoxy and up to per halo substituent C<sub>1</sub>-C<sub>10</sub> alkoxy.

**46. (Previously presented)** A compound of claim 37 which is a pharmaceutically acceptable salt of a compound of formula I selected from the group consisting of

- a) basic salts of organic acids and inorganic acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluorosulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-naphthalene sulfonic acid, 2-naphthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid; and
- b) acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations.

**47. (Previously presented)** A pharmaceutical composition comprising a compound of claim 37 or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.

**48. (Previously presented)** A method for the treatment of solid cancers, comprising administering to a host in need thereof an effective amount of a compound of Formula I of claim 37.

**49. (Previously presented)** A compound as in claim 37 wherein  $R_x$  is  $NR_aR_b$  and  $R_a$  and  $R_b$  are independently selected from hydrogen and  $C_1 - C_{10}$  alkyl.